8-K: Kyverna Therapeutics Amends Loan Facility Terms

Kyverna Therapeutics has amended its loan and security agreement with Oxford Finance LLC, extending loan availability and modifying milestone-based draw conditions.

Summary

• Kyverna Therapeutics, Inc. has amended its Loan and Security Agreement with Oxford Finance LLC, originally entered into on October 31, 2025.
• The amendment, effective as of June 30, 2026, extends the availability of the remaining $15.0 million of Term A Loans through December 31, 2026.
• An upfront cash fee of $187,500 was paid for this extension.
• If the full $15.0 million of Term A Loans is not drawn by December 31, 2026, a non-utilization fee of 1.0% on the undrawn amount will apply.
• Contingent upon drawing the full remaining $15.0 million in Term A Loans, several modifications to the Loan Facility will become effective.
• These modifications include extending the Term B Loan availability to September 30, 2027, or 90 days after a clinical milestone is achieved.
• A 1.0% non-utilization fee will also apply to the Term B Loan if not drawn by the end of its period.
• The Term C Loans will be available in two $20.0 million tranches, with availability dates tied to revenue and clinical milestones through March 31, 2028.
• Minimum revenue covenants will commence based on the aggregate gross cash proceeds from other capital sources, with potential start dates of June 30, 2027, September 30, 2027, or December 31, 2027.
• If the full remaining $15.0 million of Term A Loans is not drawn, these additional modifications will not take effect, and the original terms will apply.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it provides continued access to non-dilutive capital, it comes with additional fees and contingent conditions, and the ultimate drawdowns are dependent on future performance.

Positives

• Extension of Term A loan availability provides additional time to secure $15.0 million in funding.
• Potential for extended availability of Term B and Term C loans, subject to meeting milestones and drawing full Term A loans.
• The amendment offers flexibility in drawing down loan tranches based on clinical and revenue milestones.

Negatives

• An upfront fee of $187,500 was paid for the extension of Term A loan availability.
• A 1.0% non-utilization fee will be charged on any undrawn portion of the Term A loans if not fully drawn by December 31, 2026.
• A 1.0% non-utilization fee will apply to the Term B Loan if not drawn by the end of its period.
• The effectiveness of significant modifications to the loan facility is contingent on drawing the full remaining $15.0 million of Term A Loans.

Risks

• Failure to draw the full remaining $15.0 million of Term A Loans by December 31, 2026, will result in a 1.0% non-utilization fee on the undrawn amount and will prevent the activation of further modifications to the loan facility.
• The company may not achieve the specified clinical or revenue milestones required to draw the Term B and Term C loans.
• The company may be subject to minimum revenue covenants starting as early as the quarter ending June 30, 2027, depending on other capital sources.

Future Outlook

The company has extended the availability of its loan facility tranches, with future draws contingent on achieving specific clinical and revenue milestones. Minimum revenue covenants are also introduced, with their commencement date dependent on other capital sources.

Industry Context

StockSavvy.ai notes that extending debt facility availability is a common strategy for biotechnology companies to manage cash burn while awaiting clinical or regulatory progress. The inclusion of milestone-based draws and revenue covenants reflects the lender's risk assessment in this capital-intensive sector.

Stakeholder Impact

• Shareholders: The extension of the loan facility provides continued runway without immediate dilution, but the fees and potential non-utilization fees represent a cost. Future milestone achievement is critical for value realization.
• Lenders (Oxford Finance LLC): The amendment involves a fee and potential non-utilization fees, while also adjusting terms based on company progress and market conditions.
• Creditors: The company's ability to meet future financial obligations, including potential revenue covenants, will be influenced by the success of its development programs and financing.

Next Steps

• Kyverna Therapeutics must draw the remaining $15.0 million of Term A Loans by December 31, 2026, to avoid non-utilization fees and enable further loan modifications.
• The company needs to achieve specified clinical milestones to draw the Term B loan.
• The company needs to achieve specified revenue and clinical milestones to draw the Term C loans.
• The company must monitor its capital sources to determine the exact commencement date of minimum revenue covenants.

Key Dates

Keywords

Kyverna Therapeutics, Loan and Security Agreement, Oxford Finance LLC, Term Loan Facility, Amendment, Clinical Milestones, Revenue Milestones, Capital Raise, Non-dilutive financing, Form 8-K